Press Release
Apmonia Therapeutics announces the launch of the THROMBOTAX program with the support of the ANR (French National Research Agency)
December 5, 2022
16 h 27 min
Apmonia Therapeutics announces a 4 M€ fundraising round to complete regulatory preclinical studies of its anti-cancer immunotherapy drug candidate (AP-01) Success for Apmonia Therapeutics’ technology
Apmonia Therapeutics annonce une nouvelle levée de fonds de 4 M€ lui permettant la finalisation des études précliniques réglementaires de son candidat médicament en immunothérapie
We are pleased to announce our newest paper in Cancers MDPI is now published online! This work unveils the potential of Apmonia Therapeutics’ lead candidate TAX2 (AP-01)
Apmonia Therapeutics’ lead program (AP-01 or TAX2) is a cyclic peptide targeting TSP-1 (a ligand of CD47 receptor) across various tumor indications with high unmet